Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.

Exclusive: Australian doctors are being approached every day by teenagers and young adults – girls as well as boys – asking ...

With a new generation of weight-loss drugs entering Indian markets, spelling hope for many, The Indian Express tracks the ...

An expert said weight loss drugs might help people see faster results, which can give them encouragement to continue. But he ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...

In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...

Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...

Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with ...

"GLP-1RA microdosing trend continues despite “anecdotal evidence”" was originally created and published by Pharmaceutical ...

The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.

Mochi Health offers two subscription-based weight loss programs: Mochi Health and Wellness Plus. While anyone can access the ...